Compass therapeutics reports third quarter 2022 financial results and provides corporate update

Boston, nov. 09, 2022 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date 2022 financial results and provided a corporate update.
CMPX Ratings Summary
CMPX Quant Ranking